Drugs that contain Doravirine; Lamivudine; Tenofovir Disoproxil Fumarate
1. List of Delstrigo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8486975 | MSD MERCK CO | Non-nucleoside reverse transcriptase inhibitors |
Oct, 2031
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10603282 | MSD MERCK CO | Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine |
Nov, 2036
(13 years from now) | |
| US10842751 | MSD MERCK CO | Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine |
Nov, 2036
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 30, 2023 |
| New Patient Population (NPP) | Jan 27, 2025 |
NCE-1 date: 2022-08-30
Market Authorisation Date: 30 August, 2018
Treatment: Treatment of hiv-1 infection in adult patients as a replacement therapy in virologically suppressed adults with no history of treatment failure and no known substitutions associated with resistance to...
Dosage: TABLET;ORAL
DELSTRIGO family patents
11
United States
5
Hungary
4
Canada
4
Lithuania
4
European Union
3
Croatia
3
Denmark
3
Spain
3
Portugal
3
Poland
3
Japan
3
Slovenia
3
RS
2
Australia
2
Israel
2
Korea, Republic of
2
ME
2
Cyprus
2
Norway
2
Hong Kong
2
Mexico
2
China
2
Brazil
1
Colombia
1
Ecuador
1
Luxembourg
1
EA
1
Dominican Republic
1
Netherlands
1
New Zealand
1
Honduras
1
Tunisia
1
Peru
1
Malaysia
1
Costa Rica
1
Nicaragua
1
Chile
1
Singapore
1
Ukraine
1
Russia
1
Morocco
1
Georgia
1
Argentina
1
Taiwan
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic